The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01E | Antiglaucoma preparations and miotics | |
| 4 | S01EX | Other antiglaucoma preparations | |
| 5 | S01EX06 |
| Active Ingredient | Description | |
|---|---|---|
| Omidenepag |
Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown. Elevated IOP represents a major risk factor for glaucomatous field loss. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| OMLONTI Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
